Masalu, John P.
Okumu, Fredros O.
Mmbando, Arnold S.
Sikulu-Lord, Maggy T.
Ogoma, Sheila B.
Funding for this research was provided by:
Grand Challenges Canada (Grant number: S5 0440-01)
Wellcome Trust Intermediate Fellowship in Public Health and Tropical Medicine (Grant number: WT102350/Z/13/Z)
by Wellcome Trust Masters Fellowship (Grant number: WT106356/Z/14/Z)
Article History
Received: 19 December 2017
Accepted: 25 March 2018
First Online: 10 April 2018
Ethics approval and consent to participate
: The study was approved by the Institute Review Board of Ifakara Health Institute IHI/IRB/EXT/07 and Medical Research Coordinated Committee of the National Institute for Medical Research of the United Republic of Tanzania (NIMR/HQ/R.8a/Vol.1X/2199). Study participants were recruited after signing informed consent forms. Participants were trained on conducting HLC and how to avoid excessive exposures to mosquitoes bites. To stop malaria transmission during HLC, volunteers were given malaria prophylaxis drugs: Mefloquine (Mepha LLC, Aesch-Basel Switzerland). They were also screened for malaria parasites once every week for the entire experimental period using rapid diagnostic test kits mRDT- (MAL- Pf®, ICT Diagnostics, Cape Town, South Africa). There were no reported cases of malaria throughout the experiment. This manuscript has been approved by Dr Susan F. Rumisha, on behalf of the Director General of The National Institute for Medical Research, United Republic of Tanzania, with reference number: NIMR/HQ/P.12 VOL. XXIII/20.
: Not applicable.
: The authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.